Impact of platelet-lymphocyte ratio after robot-assisted partial nephrectomy with renorrhaphy
- PMID: 39730921
- PMCID: PMC11680792
- DOI: 10.1038/s41598-024-82197-x
Impact of platelet-lymphocyte ratio after robot-assisted partial nephrectomy with renorrhaphy
Abstract
Renorrhaphy is often performed after tumor resection during robotic-assisted laparoscopic partial nephrectomy (RAPN). This study aimed to investigate the association between renorrhaphy performance and inflammatory markers. A retrospective cohort study was conducted including patients with renal cell carcinoma who underwent RAPN at eight institutions in Japan between April 2016 and November 2023. The primary endpoint was the association between the renorrhaphy performance in RAPN and the postoperative inflammatory markers. The secondary endpoints were perioperative outcomes in patients with and without renorrhaphy. The patients were divided into two groups at the time of RAPN: those who underwent renorrhaphy (renorrhaphy group) and those who did not (omitted group). In total, 934 patients were enrolled in this study. After propensity score matching, the rate of change in C-reactive protein and neutrophil-lymphocyte ratio on postoperative day 28 were not significant difference between the two groups. In contrast, the rate of change in platelet-lymphocyte ratio (PLR) on postoperative day 28 was significantly higher in renorrhaphy group than omitted group. Regarding surgical outcomes, the renorrhaphy group had a significantly longer hospital stay, operative time, and warm ischemia time (P = 0.038, P = 0.022, and P = 0.009, respectively) than the omitted group did. Furthermore, the omitted group had a significantly higher rate of Trifecta achievement than the renorrhaphy group did. This study demonstrated that renorrhaphy performance in RAPN was significantly associated with the higher value of postoperative PLR.
Keywords: Platelet-to-lymphocyte ratio; Renal cell carcinoma; Renorrhaphy; Robot-assisted partial nephrectomy.
© 2024. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests. Ethics approval: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Mie University (January 4, 2023 / H2022-114). Consent to participate: Owing to the retrospective observational nature of this study, the need for informed consent was waived. Consent for publication: Patient consents were not applicable for this retrospective study.
References
-
- Sasaki, T. et al. Urological cancer statistics on incidence from 1975 to 2019 and mortality from 1958 to 2022 in Japan. Int. J. Clin. Oncol.29, 1088–1095 (2024). - PubMed
-
- Ljungberg, B. et al. European association of urology guidelines on renal cell carcinoma: the 2022 update. Eur. Urol.82, 399–410 (2022). - PubMed
-
- Campbell, S. C. et al. Renal mass and localized renal cancer: evaluation, management, and follow-up: AUA guideline: part I. J. Urol.206, 199–208 (2021). - PubMed
-
- Porpiglia, F. et al. Partial nephrectomy in clinical T1b renal tumors: multicenter comparative study of open, laparoscopic and robot-assisted approach (the RECORd Project). Urology89, 45–53 (2016). - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
